Dose investigation of superparamagnetic iron oxide (SPIO) SH U 555 A in liver MR imaging

Hirohashi Shinji, Ichikawa Tomoaki, Akihiro Tanimoto, Isobe Yoshinori, Hachiya Junichi, Saito Kazuhiro, Isoda Hiroyoshi, Nishimura Hiroshi, Kuwatsuru Ryohei, Gokan Takehiko, Murakami Takamichi, Nakano Shigeyuki, Seriu Taku

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

SH U 555 A, a new superparamagnetic iron oxide(SPIO)contrast agent for liver MR imaging, was investigated in terms of safety and efficacy. Eighty-four patients with suspected malignant liver tumor were randomly allocated to two groups: the L dose group (8 μmol Fe/kg) and H dose group (12 μmol Fe/kg). Efficacy was qualitatively evaluated through blinded reading of the MR images. Assessment of the images revealed no consistent differences between the L and H dose groups. During the 3- to 4-day observation period, a total of 16 adverse events were observed in 11 patients: 8 patients in the L dose group and 3 patients in the H dose group. Nasal bleeding occurred in 2 of these cases in the H dose group 2 and 4 days, respectively, after injection. Although patients in the H dose group showed a significantly larger transient decrease in Coagulation Factor XI at 4-6 hr post-injection (p. i.) than patients in the L dose group, analysis of covariance revealed an estimated 6.5% difference. There was no prolongation of APTT or change in Factor XI at 72-96 hr p. i. Because there were no clinically significant differences between the L and H doses, both were considered to be safe and effective.

Original languageEnglish
Pages (from-to)539-550
Number of pages12
JournalNippon Acta Radiologica
Volume63
Issue number9
Publication statusPublished - 2003 Nov 25

Fingerprint

Liver
Factor XI
Epistaxis
Injections
Contrast Media
ferric oxide
Reading
Observation
Safety
Neoplasms

Keywords

  • Contrast media
  • Liver tumor
  • MRI
  • Superparamagnetic iron oxides (SPIO)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shinji, H., Tomoaki, I., Tanimoto, A., Yoshinori, I., Junichi, H., Kazuhiro, S., ... Taku, S. (2003). Dose investigation of superparamagnetic iron oxide (SPIO) SH U 555 A in liver MR imaging. Nippon Acta Radiologica, 63(9), 539-550.

Dose investigation of superparamagnetic iron oxide (SPIO) SH U 555 A in liver MR imaging. / Shinji, Hirohashi; Tomoaki, Ichikawa; Tanimoto, Akihiro; Yoshinori, Isobe; Junichi, Hachiya; Kazuhiro, Saito; Hiroyoshi, Isoda; Hiroshi, Nishimura; Ryohei, Kuwatsuru; Takehiko, Gokan; Takamichi, Murakami; Shigeyuki, Nakano; Taku, Seriu.

In: Nippon Acta Radiologica, Vol. 63, No. 9, 25.11.2003, p. 539-550.

Research output: Contribution to journalArticle

Shinji, H, Tomoaki, I, Tanimoto, A, Yoshinori, I, Junichi, H, Kazuhiro, S, Hiroyoshi, I, Hiroshi, N, Ryohei, K, Takehiko, G, Takamichi, M, Shigeyuki, N & Taku, S 2003, 'Dose investigation of superparamagnetic iron oxide (SPIO) SH U 555 A in liver MR imaging', Nippon Acta Radiologica, vol. 63, no. 9, pp. 539-550.
Shinji H, Tomoaki I, Tanimoto A, Yoshinori I, Junichi H, Kazuhiro S et al. Dose investigation of superparamagnetic iron oxide (SPIO) SH U 555 A in liver MR imaging. Nippon Acta Radiologica. 2003 Nov 25;63(9):539-550.
Shinji, Hirohashi ; Tomoaki, Ichikawa ; Tanimoto, Akihiro ; Yoshinori, Isobe ; Junichi, Hachiya ; Kazuhiro, Saito ; Hiroyoshi, Isoda ; Hiroshi, Nishimura ; Ryohei, Kuwatsuru ; Takehiko, Gokan ; Takamichi, Murakami ; Shigeyuki, Nakano ; Taku, Seriu. / Dose investigation of superparamagnetic iron oxide (SPIO) SH U 555 A in liver MR imaging. In: Nippon Acta Radiologica. 2003 ; Vol. 63, No. 9. pp. 539-550.
@article{4d0b355759c641cc9cdb0dd2599db2cf,
title = "Dose investigation of superparamagnetic iron oxide (SPIO) SH U 555 A in liver MR imaging",
abstract = "SH U 555 A, a new superparamagnetic iron oxide(SPIO)contrast agent for liver MR imaging, was investigated in terms of safety and efficacy. Eighty-four patients with suspected malignant liver tumor were randomly allocated to two groups: the L dose group (8 μmol Fe/kg) and H dose group (12 μmol Fe/kg). Efficacy was qualitatively evaluated through blinded reading of the MR images. Assessment of the images revealed no consistent differences between the L and H dose groups. During the 3- to 4-day observation period, a total of 16 adverse events were observed in 11 patients: 8 patients in the L dose group and 3 patients in the H dose group. Nasal bleeding occurred in 2 of these cases in the H dose group 2 and 4 days, respectively, after injection. Although patients in the H dose group showed a significantly larger transient decrease in Coagulation Factor XI at 4-6 hr post-injection (p. i.) than patients in the L dose group, analysis of covariance revealed an estimated 6.5{\%} difference. There was no prolongation of APTT or change in Factor XI at 72-96 hr p. i. Because there were no clinically significant differences between the L and H doses, both were considered to be safe and effective.",
keywords = "Contrast media, Liver tumor, MRI, Superparamagnetic iron oxides (SPIO)",
author = "Hirohashi Shinji and Ichikawa Tomoaki and Akihiro Tanimoto and Isobe Yoshinori and Hachiya Junichi and Saito Kazuhiro and Isoda Hiroyoshi and Nishimura Hiroshi and Kuwatsuru Ryohei and Gokan Takehiko and Murakami Takamichi and Nakano Shigeyuki and Seriu Taku",
year = "2003",
month = "11",
day = "25",
language = "English",
volume = "63",
pages = "539--550",
journal = "Nippon Acta Radiologica",
issn = "0048-0428",
publisher = "Japan Radiological Society",
number = "9",

}

TY - JOUR

T1 - Dose investigation of superparamagnetic iron oxide (SPIO) SH U 555 A in liver MR imaging

AU - Shinji, Hirohashi

AU - Tomoaki, Ichikawa

AU - Tanimoto, Akihiro

AU - Yoshinori, Isobe

AU - Junichi, Hachiya

AU - Kazuhiro, Saito

AU - Hiroyoshi, Isoda

AU - Hiroshi, Nishimura

AU - Ryohei, Kuwatsuru

AU - Takehiko, Gokan

AU - Takamichi, Murakami

AU - Shigeyuki, Nakano

AU - Taku, Seriu

PY - 2003/11/25

Y1 - 2003/11/25

N2 - SH U 555 A, a new superparamagnetic iron oxide(SPIO)contrast agent for liver MR imaging, was investigated in terms of safety and efficacy. Eighty-four patients with suspected malignant liver tumor were randomly allocated to two groups: the L dose group (8 μmol Fe/kg) and H dose group (12 μmol Fe/kg). Efficacy was qualitatively evaluated through blinded reading of the MR images. Assessment of the images revealed no consistent differences between the L and H dose groups. During the 3- to 4-day observation period, a total of 16 adverse events were observed in 11 patients: 8 patients in the L dose group and 3 patients in the H dose group. Nasal bleeding occurred in 2 of these cases in the H dose group 2 and 4 days, respectively, after injection. Although patients in the H dose group showed a significantly larger transient decrease in Coagulation Factor XI at 4-6 hr post-injection (p. i.) than patients in the L dose group, analysis of covariance revealed an estimated 6.5% difference. There was no prolongation of APTT or change in Factor XI at 72-96 hr p. i. Because there were no clinically significant differences between the L and H doses, both were considered to be safe and effective.

AB - SH U 555 A, a new superparamagnetic iron oxide(SPIO)contrast agent for liver MR imaging, was investigated in terms of safety and efficacy. Eighty-four patients with suspected malignant liver tumor were randomly allocated to two groups: the L dose group (8 μmol Fe/kg) and H dose group (12 μmol Fe/kg). Efficacy was qualitatively evaluated through blinded reading of the MR images. Assessment of the images revealed no consistent differences between the L and H dose groups. During the 3- to 4-day observation period, a total of 16 adverse events were observed in 11 patients: 8 patients in the L dose group and 3 patients in the H dose group. Nasal bleeding occurred in 2 of these cases in the H dose group 2 and 4 days, respectively, after injection. Although patients in the H dose group showed a significantly larger transient decrease in Coagulation Factor XI at 4-6 hr post-injection (p. i.) than patients in the L dose group, analysis of covariance revealed an estimated 6.5% difference. There was no prolongation of APTT or change in Factor XI at 72-96 hr p. i. Because there were no clinically significant differences between the L and H doses, both were considered to be safe and effective.

KW - Contrast media

KW - Liver tumor

KW - MRI

KW - Superparamagnetic iron oxides (SPIO)

UR - http://www.scopus.com/inward/record.url?scp=1542547085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542547085&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 539

EP - 550

JO - Nippon Acta Radiologica

JF - Nippon Acta Radiologica

SN - 0048-0428

IS - 9

ER -